Early and Late Neutrophil CD64 and Monocyte HLA-DR as Biomarkers for Septic Shock

Study Summary: Neutrophil CD64 & Monocyte HLA-DR in Septic Shock

What is studied?

Doctors looked at two blood markers:

• Neutrophil CD64 (nCD64): rises quickly when the body fights infection.
• Monocyte HLA-DR (mHLA-DR): falls when the immune system becomes weak or "paralyzed." They also calculated a Sepsis Index (ratio of nCD64 to HLA-DR) to see how these markers change in patients with septic shock.

Why is this important? Septic shock is a severe form of sepsis that can cause organ failure and death. Early detection and knowing which patients are at higher risk can guide treatment and improve survival.

How was it done?

• Blood samples were taken on Day 1 (early) and Day 8 (late).
• Results will be compared between survivors and non-survivors.
• 20 healthy people provided baseline values for comparison.

What does this mean? - Monitoring these markers over time (not just once) may helps doctors understand whether a patient's immune system is recovering or worsening.

Take-home message

For patients and families:

- Septic shock is serious, but doctors now have better tools to track how the body is responding.

Study Overview

• Status: Completed
• Conditions: Sepsis; Septic Shock

Detailed Description

Detailed Protocol of the Study

1. Title Early and late neutrophil CD64 and monocyte HLA-DR as biomarkers for septic shock.

2. Study Design

   • Type: Prospective, single-center, observational cohort study.
   • Setting: Medical ICU of a tertiary care university teaching hospital in northern India.
   • Duration: January 2019 - December 2019.
   • Ethics Approval: Biomedical Research and Ethics Committee (BREC/18/194).
   • Guidelines: Conducted in adherence with STROBE reporting standards.

3. Objectives

   - Primary Objective: To evaluate neutrophil CD64 (nCD64), monocyte HLA-DR (mHLA-DR), and the Sepsis Index as prognostic markers in septic shock.

   • Secondary Objectives:
   • Compare biomarker levels between survivors and non-survivors.
   • Assess predictive accuracy of these markers for 28-day mortality using ROC analysis.

4. Study Population

   • Inclusion Criteria:
   • Age ≥18 years.
   • Diagnosis of septic shock according to prevailing Sepsis-3 criteria.
   • Written informed consent from patient or next of kin.
   • Exclusion Criteria:
   • Pregnant females.
   • Active malignancy.
   • Severe chronic liver disease.
   • Chronic kidney disease requiring maintenance hemodialysis.
   • Immunocompromised patients or those on immunomodulatory therapy prior to sepsis onset.
   • Non-bacterial sepsis (viral, fungal, tubercular).

5. Enrollment & Sample Size

   • Screened: 80 patients.
   • Excluded: 24 (per exclusion criteria).
   • Final cohort: 56 patients (37 survivors, 19 non-survivors).
   • Controls: 20 healthy volunteers for baseline biomarker values.

6. Data Collection

   • Demographics: Age, sex, residence, BMI, smoking status.
   • Clinical variables: Primary diagnosis, comorbidities, severity scores (qSOFA, SIRS, APACHE II), vital signs, organ dysfunction parameters (PaO₂/FiO₂, inotropic support, renal replacement therapy, GCS).
   • Laboratory parameters: CBC, renal/liver function tests, ABG, primary diagnosis details.
   • Outcome measures: ICU stay, ventilator days, 28-day mortality.

7. Biomarker Assessment

   • Markers:
   • Neutrophil CD64 (nCD64).
   • Monocyte HLA-DR (mHLA-DR).
   • Sepsis Index = nCD64 ÷ mHLA-DR.
   • Method: Flow cytometry (8-color FACS Canto II, BD Biosciences).
   • Units: Mean Fluorescence Intensity (MFI).
   • Time points:
   • Day 1 (admission).
   • Day 8 (follow-up).

8. Statistical Analysis

   • Software: SPSS v24 (IBM).
   • Descriptive statistics: Mean ± SD for normal data; median (IQR) for skewed data.
   • Comparisons:
   • Independent t-test for normal distribution.
   • Mann-Whitney U test for skewed data.
   • Predictive analysis: ROC curves for nCD64, HLA-DR, and Sepsis Index.
   • Significance threshold: p < 0.05 (two-sided).

9. Outcomes

   • Primary outcome: 28-day mortality.
   • Secondary outcomes: ICU stay duration, ventilator days, organ dysfunction severity.

10. Safety & Compliance

    • Biomedical waste: Managed per Biomedical Waste (Management and Handling) Rules.
    • Patient safety: Standard ICU protocols followed; no intervention beyond routine care.

• Study Type: Observational
• Enrollment (Actual): 76

Contacts and Locations

Study Locations

• India
  • Haryana
    • Rohtak, Haryana, India, 124001
      • Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

All patients aged over 18 years with a diagnosis of septic shock

Description

Inclusion Criteria: Patients were eligible if they met all of the following:

• Age ≥ 18 years.
• Diagnosis of septic shock according to prevailing Sepsis-3 criteria at the time of study.
• Admission to the medical ICU of the tertiary care teaching hospital.
• Written informed consent obtained from patient or next of kin.

Exclusion Criteria: Patients were excluded if they met any of the following:

• Pregnant females.
• Active malignancy (any known cancer diagnosis).
• Severe chronic liver disease.
• Chronic kidney disease requiring maintenance hemodialysis.
• Immunocompromised state, including:
• HIV/AIDS.
• Long-term corticosteroid therapy.
• Other immunosuppressive conditions.
• Prior immunomodulatory treatment before onset of sepsis (e.g., biologics, GM-CSF, interferons).
• Non-bacterial sepsis, including:
• Viral sepsis.
• Fungal sepsis.
• Tubercular sepsis.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Control group
Septic shock group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure the concentration of nCD64, mHLA-DR in mean fluorescence intensity (MFI) on day 1 and 8	Sample Collection: Peripheral blood samples taken from patients with septic shock.; Technique: Flow cytometry using an 8-color FACS Canto II (BD Biosciences).; Units: Results expressed as Mean Fluorescence Intensity (MFI).; Calculation:; nCD64 measured directly on neutrophils.; mHLA-DR measured directly on monocytes.	from day of enrollment to day 8
To compare sepsis index on day 1 and day 8	Sepsis Index = nCD64 ÷ mHLA-DR.	From day of enrollment to day 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare the concentration of nCD64, mHLA-DR MFI between survivors and non-survivors.	Population: septic shock patients (survivors and non-survivors).; Time points: Day 1 (early) and Day 8 (late).; Markers: nCD64 (neutrophil CD64), mHLA-DR (monocyte HLA-DR); Outcome: 28-day mortality.	from enrollment to day 28

Collaborators and Investigators

• Sponsor: Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak
• Investigators: Study Director: Dhruva Chaudhry, MBBS,MD,DM, Pandit BD Sharma Postgraduate Institute of Medical Sciences

Study record dates

Study Major Dates

• Study Start (Actual): January 5, 2019
• Primary Completion (Actual): December 31, 2019
• Study Completion (Actual): December 31, 2019

Study Registration Dates

• First Submitted: January 14, 2026
• First Submitted That Met QC Criteria: February 3, 2026
• First Posted (Actual): February 10, 2026

Study Record Updates

• Last Update Posted (Actual): February 10, 2026
• Last Update Submitted That Met QC Criteria: February 3, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: sepsis; HLADR; NCD64; septic-shock
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Shock; Pathological Conditions, Signs and Symptoms; Sepsis; Shock, Septic
• Other Study ID Numbers: BREC/18/194

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No